These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 30317986)

  • 41. Inclisiran for the treatment of dyslipidemia.
    Nishikido T; Ray KK
    Expert Opin Investig Drugs; 2018 Mar; 27(3):287-294. PubMed ID: 29451410
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PCSK9 and Hypercholesterolemia: Therapeutic Approach.
    Obradovic M; Zaric B; Sudar-Milovanovic E; Ilincic B; Stokic E; Perovic M; Isenovic ER
    Curr Drug Targets; 2018; 19(9):1058-1067. PubMed ID: 29210646
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
    Ridker PM; Rose LM; Kastelein JJP; Santos RD; Wei C; Revkin J; Yunis C; Tardif JC; Shear CL;
    J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events.
    Turgeon RD; Pearson GJ
    Am J Health Syst Pharm; 2018 Jun; 75(11):747-754. PubMed ID: 29802110
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [PCSK9 inhibitors : New treatment option in clinical practice].
    Müller-Wieland D; Marx N
    Herz; 2016 Jun; 41(4):290-5. PubMed ID: 27215418
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia.
    Verbeek R; Stoekenbroek RM; Hovingh GK
    Eur J Pharmacol; 2015 Sep; 763(Pt A):38-47. PubMed ID: 25989132
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PCSK9 Inhibition-Based Therapeutic Approaches: An Immunotherapy Perspective.
    Momtazi-Borojeni AA; Pirro M; Xu S; Sahebkar A
    Curr Med Chem; 2022; 29(6):980-999. PubMed ID: 34711156
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hepatic HNF1 transcription factors control the induction of PCSK9 mediated by rosuvastatin in normolipidemic hamsters.
    Dong B; Singh AB; Shende VR; Liu J
    Int J Mol Med; 2017 Mar; 39(3):749-756. PubMed ID: 28204827
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Small molecules as inhibitors of PCSK9: Current status and future challenges.
    Xu S; Luo S; Zhu Z; Xu J
    Eur J Med Chem; 2019 Jan; 162():212-233. PubMed ID: 30448414
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia.
    Awan Z; Baass A; Genest J
    Clin Chem; 2014 Nov; 60(11):1380-9. PubMed ID: 25248569
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.
    Tziomalos K
    Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dyslipidaemias and Cardiovascular Disease: Focus on the Role of PCSK9 Inhibitors.
    Panagiotopoulou O; Chiesa ST; Tousoulis D; Charakida M
    Curr Med Chem; 2020; 27(27):4494-4521. PubMed ID: 31453780
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PCSK9 and cancer: Rethinking the link.
    Mahboobnia K; Pirro M; Marini E; Grignani F; Bezsonov EE; Jamialahmadi T; Sahebkar A
    Biomed Pharmacother; 2021 Aug; 140():111758. PubMed ID: 34058443
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel treatment options for the management of heterozygous familial hypercholesterolemia.
    Polychronopoulos G; Tziomalos K
    Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1375-1381. PubMed ID: 28884604
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease.
    Cao G; Qian YW; Kowala MC; Konrad RJ
    Endocr Metab Immune Disord Drug Targets; 2008 Dec; 8(4):238-43. PubMed ID: 19075777
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drugs for hypercholesterolaemia - from statins to pro-protein convertase subtilisin kexin 9 (PCSK9) inhibition.
    Wierzbicki AS; Grant P
    Clin Med (Lond); 2016 Aug; 16(4):353-7. PubMed ID: 27481380
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
    Dragan S; Serban MC; Banach M
    J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):157-68. PubMed ID: 24938457
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PCSK9 inhibitors: an overview on a new promising lipid-lowering therapy.
    Denegri A; Petrova-Slater I; Pasotti E; Rossi MG; Pedrazzini GB; Moccetti T; Moccetti M
    J Cardiovasc Med (Hagerstown); 2016 Apr; 17(4):237-44. PubMed ID: 26855411
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Lipid-lowering drugs and PCSK9].
    Millán Núñez-Cortés J; Mostaza Prieto JM
    Clin Investig Arterioscler; 2016 May; 28 Suppl 2():9-13. PubMed ID: 27888906
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Proprotein convertase subtilisin/kexin type 9 inhibition in cardiovascular disease: current status and future perspectives.
    Cho KH; Hong YJ
    Korean J Intern Med; 2020 Sep; 35(5):1045-1058. PubMed ID: 32921006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.